On October 8, 2026, the U.S. Food and Drug Administration (FDA) announced the approval of atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment. This approval is indicated for adult and pediatric patients aged 2 years and older diagnosed with Stage III mismatch repair deficient (dMMR) colon cancer.

This new treatment option represents a significant advancement in managing Stage III dMMR colon cancer by incorporating immunotherapy alongside established chemotherapy agents. The combination aims to improve patient outcomes by targeting the cancer through multiple mechanisms.

Healthcare providers should consider this newly approved regimen within the context of individual patient needs and clinical judgment. The approval underscores the FDA's commitment to expanding therapeutic options for patients with challenging malignancies.